Page 36 - 2020_07-Haematologica-web

E. Hellström-Lindberg et al.
119. Leitch HA, Buckstein R, Zhu N, et al. Iron overload in myelodysplastic syndromes: evi- dence based guidelines from the Canadian consortium on MDS. Leuk Res. 2018;74:21- 41.
120. Killick SB. Iron chelation therapy in low risk myelodysplastic syndrome. Br J Haematol. 2017;177(3):375-387.
121.Meerpohl JJ, Antes G, Ruecker G, et al. Deferasirox for managing iron overload in people with myelodysplastic syndrome. Cochrane Database Syst Rev. 2010;(11): CD007461.
122.Steensma DP, Gattermann N. When is iron overload deleterious, and when and how should iron chelation therapy be adminis- tered in myelodysplastic syndromes? Best Pract Res Clin Haematol. 2013;26(4):431- 444.
123. Fenaux P, Santini V, Spiriti MAA, et al. A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-alpha in anemic patients with low- risk MDS. Leukemia. 2018;32(12):2648- 2658.
124.Platzbecker U, Symeonidis A, Oliva EN, et al. A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with ane- mia and lower-risk myelodysplastic syn- dromes. Leukemia. 2017;31(9):1944-1950.
125. Park S, Kelaidi C, Meunier M, et al. The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion. Ann Hematol. 2020;99(1):7- 19.
126.Balleari E, Filiberti RA, Salvetti C, et al. Effects of different doses of erythropoietin in patients with myelodysplastic syn- dromes: a propensity score-matched analy- sis. Cancer Med. 2019;8(18):7567-7576.
127. Garelius HK, Johnston WT, Smith AG, et al. Erythropoiesis-stimulating agents signifi- cantly delay the onset of a regular transfu- sion need in nontransfused patients with lower-risk myelodysplastic syndrome. J Intern Med. 2017;281(3):284-299.
128.Negrin RS, Stein R, Doherty K, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombi- nant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood. 1996;87(10):4076-4081.
129. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al. Treatment of anemia in myelodysplas- tic syndromes with granulocyte colony- stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood. 1998;92(1):68-75.
130. Jadersten M, Malcovati L, Dybedal I, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syn- drome. J Clin Oncol. 2008;26(21):3607-3613.
131. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syn- drome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456-1465.
132. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion- dependent, low-risk, and intermediate-1– risk myelodysplastic syndromes with kary- otypes other than deletion 5q. Blood. 2008;111(1):86-93.
133. Toma A, Kosmider O, Chevret S, et al. Lenalidomide with or without erythropoi- etin in transfusion-dependent erythro- poiesis-stimulating agent-refractory lower- risk MDS without 5q deletion. Leukemia. 2016;30(4):897-905.
134.
Mossner M, Jann J-C, Nowak D, et al. Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS). Leukemia. 2016;30(9):1956-1959.
azacitidine. Blood. 2011;117(2):403-411. 148.Hwang KL, Song MK, Shin HJ, et al. Monosomal and complex karyotypes as prognostic parameters in patients with International Prognostic Scoring System higher risk myelodysplastic syndrome treat- ed with azacitidine. Blood Res. 2014;49
(4):234-240.
149.Bejar R, Lord A, Stevenson K, et al. TET2
mutations predict response to hypomethy- lating agents in myelodysplastic syndrome patients. Blood. 2014;124(17):2705-2712.
150. Traina F, Visconte V, Elson P, et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia. 2014;28(1):78- 87.
151.Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011;25(7):1147-1152.
152. Jin J, Hu C, Yu M, et al. Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis. PLoS One. 2014;9(6):e100206.
153.Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine adminis- tered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol. 2009;27 (23):3842-3848.
154. Kantarjian HM, O'Brien S, Shan J, et al. Update of the decitabine experience in high- er risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer. 2007;109(2):265-273.
155.Welch JS, Petti AA, Miller CA, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med. 2016;375(21):2023-2036.
156.de Witte T, Suciu S, Peetermans M, et al. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia. 1995;9(11):1805-1811.
135.Sloand EM, Wu CO, Greenberg P, et al. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol. 2008;26(15):2505-2511.
136. Kadia TM, Borthakur G, Garcia-Manero G, et al. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony- stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol. 2012;157(3):312-320.
137.
Passweg JR, Giagounidis AA, Simcock M, et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospec- tive randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care-- SAKK 33/99. J Clin Oncol. 2011;29(3):303- 309.
138. Stahl M, DeVeaux M, de Witte T, et al. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood Adv. 2018;2(14):1765-1772.
139.Stahl M, Bewersdorf JP, Giri S, et al. Use of immunosuppressive therapy for manage- ment of myelodysplastic syndromes: a sys- tematic review and meta-analysis. Haematologica. 2020;105(1):102-111.
140. Silverman LR, Holland JF, Weinberg RS, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 1993;7(Suppl 1):21-29.
141.Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azaciti- dine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002;20 (10):2429-2440.
142. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24(24):3895-3903.
143. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232.
144.Komrokji R, Swern AS, Grinblatt D, et al. Azacitidine in lower-risk myelodysplastic syndromes: a meta-analysis of data from prospective studies. Oncologist. 2018;23 (2):159-70.
145.Tobiasson M, Dybedahl I, Holm MS, et al. Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resis- tant, low- and Int-1-risk MDS: results from the Nordic NMDSG08A phase II trial. Blood Cancer J. 2014;4:e189.
146. Garcia-Manero G, Jabbour E, Borthakur G, et al. Randomized open-label phase II study of decitabine in patients with low- or inter- mediate-risk myelodysplastic syndromes. J Clin Oncol. 2013;31(20):2548-2553.
147.Itzykson R, Thepot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with
157.
Ganser A, Heil G, Seipelt G, et al. Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk acute myeloid leukemia (AML). Ann Hematol. 2000;79(1):30-35.
158.Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodys- plastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106(5): 1090-1098.
159.Martino R, Iacobelli S, Brand R, et al. Retrospective comparison of reduced-inten- sity conditioning and conventional high- dose conditioning for allogeneic hematopoi- etic stem cell transplantation using HLA- identical sibling donors in myelodysplastic syndromes. Blood. 2006;108(3):836-846.
160. Koenecke C, Gohring G, de Wreede LC, et al. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective
1778
haematologica | 2020; 105(7)